International Ophthalmology

, Volume 38, Issue 6, pp 2669–2675 | Cite as

Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report

Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor
  • Morara Mariachiara
  • Ruatta Celeste
  • Foschi FedericoEmail author
  • Balducci Nicole
  • Ciardella Antonio
Case Report



To report a case of a choroidal metastasis from a non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation, which responded to Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor (TKI).


First- and second-generation EGFR-TKis have been widely used for advanced NSCLC patients; however, acquired resistance to these inhibitors, as T790M mutation, could be present in resistant cases. Third-generation EGFR-TKis have emerged as potential therapeutics to overcome this resistance.


A 54-year-old lady, affected by pulmonary adenocarcinoma with systemic metastases, was diagnosed with choroidal metastasis and since tumor biopsy was positive for the EGFR-T790M mutation, she was included in ASTRIS study, and she received 80 mg tablet of Osimertinib once a day.


After a 2-week course of daily therapy with Osimertinib, the improvement of visual acuity was evident with the marked disappearance of visual field defects. We also report a dramatic anatomical reduction of choroidal mass on fundus examination and SD-OCT. These features remained stable at the 4-month follow-up visit.


This report demonstrates that Osimertinib is effective for choroidal metastasis of NSCLC harboring an EGFR-T790M mutation, which has progressed on or after first- or second-generation EGFR-TKI therapy.


Osimertinib Choroidal metastasis Carcinoma Non-small-cell lung Receptor Epidermal growth factor Tyrosine kinase inhibitor 


Compliance with ethical standards

Conflict of interest

All the authors have any financial/conflicting interest to disclose.


  1. 1.
    Shah SU, Mashayekhi A, Shields CL (2014) Uveal metastasis from lung cancer: clinical features, treatment, and outcome in 194 patients. Ophthalmology 121:352–357CrossRefGoogle Scholar
  2. 2.
    Munzone E, Nolè F, Sanna G et al (2005) Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab. Breast 14(5):380–383CrossRefGoogle Scholar
  3. 3.
    Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the EGFR pathway for cancer therapy. Clin Cancer Res 7:2958–2970PubMedGoogle Scholar
  4. 4.
    Chen CJ, McCoy AN, Brahmer J (2011) Emerging treatment for choroidal metastasis. Surv Ophthalmol 56(6):511–521CrossRefGoogle Scholar
  5. 5.
    Maturu VN, Singh N, Bensal P (2014) Combination of intravitreal Bevacizumab and systemic therapy for choroidal metastases from lung cancer: report of two cases and a systemic review of literature. Med Oncol 31:901CrossRefGoogle Scholar
  6. 6.
    Carpenter G (1987) Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56:881–914CrossRefGoogle Scholar
  7. 7.
    John T, Liu G, Tsao M-S (2009) Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for prediction of response to tyrosine kinase inhibitors. Oncogene 28(S1):S14–S23CrossRefGoogle Scholar
  8. 8.
    Chen CJ, McCoy AN, Brahmer J et al (2011) Emerging treatment for choroidal metastases. Surv Ophthalmol 56:511–521CrossRefGoogle Scholar
  9. 9.
    Daniels AB, Miller ML, Kotecha A et al (2010) Uveal metastasis from nonsmall cell lung carcinoma with dramatic response to erlotinib. Retin Cases Brief Rep 4:390–393CrossRefGoogle Scholar
  10. 10.
    Jerram AH, Smith PF, Darlington CL (1996) A dose-response analysis of the behavioral effects of (+)MK-801 in guinea pig: comparison with CPP. Pharmacol Biochem Behav 53:799–807CrossRefGoogle Scholar
  11. 11.
    Ye X, Kaliki S, Shields CL (2014) Rapid regression of choroidal metastasis from lung cancer using Erlotinib (Tarceva). Oman J Ophthalmol 7:75–77CrossRefGoogle Scholar
  12. 12.
    Desai C, Mehta A, Mishra D (2014) Usage patterns of biomarkers in non-small-cell lung cancer patients in India: findings from a systematic review and survey. Lung India 31:249–259CrossRefGoogle Scholar
  13. 13.
    Ovcaricek T, Cufer T, Kern I (2013) Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications. J Cancer Res Ther 9:261–266CrossRefGoogle Scholar
  14. 14.
    Mok TS, Wu YL, Thongprasert S (2009) Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957CrossRefGoogle Scholar
  15. 15.
    Cross DA, Ashton SE, Ghiorghiu S (2014) AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 4:1046–1061CrossRefGoogle Scholar
  16. 16.
    Kim Y, Ko J, Cui Z (2012) The EGFR T790M mutation in acquired resistance to an irreversible second-generation EGFR inhibitor. Mol Cancer Ther 11:784–791CrossRefGoogle Scholar
  17. 17.
    Jänne JA, Yang JC, Kim DW (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689–1699CrossRefGoogle Scholar
  18. 18.
    Tang ZH, Cao WX, Su MX et al (2017) Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lug cancer cells. Toxicol Appl Pharmacol 321:18–26CrossRefGoogle Scholar
  19. 19.
    Maskell D, Geropantas K, Kouroupis M (2017) Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs? Can J Ophthalmol 52:e22–e25CrossRefGoogle Scholar
  20. 20.
    Saad N, Poudel A, Basnet A et al (2017) Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291). Onco Targets Ther 10:1757–1766CrossRefGoogle Scholar
  21. 21.
    Nair AG, Asnani HT, Mehta VC et al (2017) Tyrosine kinase inhibitors in the treatment of choroidal metastases from non-small-cell lung cancer: a case report and review of literature. Ocul Oncol Patol 3:28–33CrossRefGoogle Scholar
  22. 22.
    Patino CM, Varma R, Azen SP (2011) The impact of change in visual field on health-related quality of life: the Los Angeles Latino eye study. Ophthalmology 118(7):1310–1317PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Morara Mariachiara
    • 1
  • Ruatta Celeste
    • 2
  • Foschi Federico
    • 2
    Email author
  • Balducci Nicole
    • 1
  • Ciardella Antonio
    • 1
  1. 1.Ophthalmology Unit, S. Orsola-Malpighi HospitalUniversity of BolognaBolognaItaly
  2. 2.University of BolognaBolognaItaly

Personalised recommendations